Company: BLRX
Filing Date: 2025-01-07
Form Type: 6-K
Source: 0001178913-25-000047
Chunk: 1

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 6-K
Chunk 1
---
. The Ordinary Warrants have an exercise price of $0.20 per ADS, subject to adjustment as set forth therein, are immediately exercisable, and will have a 5-year term from the issuance date. The Pre-Funded Warrants and, if at the time of exercise there is no effective registration statement registering the ADSs underlying the Ordinary Warrants, the Ordinary Warrants, may be exercised on a cashless basis. A holder of the Warrants will not have the right to exercise any portion of its Pre-Funded Warrants and Ordinary Warrants if the holder (together with such holder’s affiliates, and any persons acting as a group together with such holder or any of such holder’s affiliates or any other persons whose beneficial ownership of ADSs or ordinary shares would be aggregated with the holder’s or any of the holder’s affiliates), would beneficially own ordinary shares (including ordinary shares represented by ADSs) in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of the ordinary shares outstanding immediately after giving effect to such exercise. Under the Purchase Agreement, the Company has agreed not to (i) enter into any agreement to issue or announce the issuance or proposed issuance of any ADSs, ordinary shares or ordinary share equivalents, or (ii) file any registration statement or amendment or supplement thereto, for a period of 60 days following the closing of the Offering, subject to certain customary exceptions. In addition, the Purchase Agreement provides that for a period of one year following the closing of the Offering, the Company will not effect or enter into an agreement to effect a “variable rate transaction” as defined in the Purchase Agreement, provided that the Company may issue ADSs and/or ordinary shares under an at the market offering program with the Placement Agent (as defined below) as the sales agent following the date that is 60 days after the closing of the Offering. The Purchase Agreement also contains representations, warranties, indemnification and other provisions customary for transactions of this nature. The Company also entered into a letter agreement (the “Placement Agent Agreement”) with H.C. Wainwright & Co., LLC (the “Placement Agent”), pursuant to which the Placement Agent agreed to serve as the exclusive placement agent for the Company in connection with the Offering. The Company agreed to pay the Placement Agent a placement agent fee equal to 7% of the gross proceeds from the sale of the securities in the Offering, a management fee equal to 1% of the gross proceeds from